Advanced

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio

Aus, G; Becker, Charlotte LU ; Franzen, S; Lilja, Hans LU ; Lodding, P and Hugosson, J (2004) In European Urology 45(2). p.160-165
Abstract
Objective: To evaluate the cumulative risk of having a prostate cancer diagnosis in a repeated screening situation in relation to the free-to-total prostate specific antigen ratio (F/T-PSA). Patients and Methods: The present study includes 1385 men (aged 50-70 years) who underwent prostate biopsy for the first time in the screening program that started in 1995. In case of a benign finding, the men have been followed biennially and new biopsies performed in case of persistently elevated PSA. The cumulative risk to be diagnosed with prostate cancer until July 1, 2002 was calculated by the Kaplan-Meier method and comparison was made between different levels of T-PSA and F/T-PSA ratios. Results: Of 2129 biopsies 469 showed cancer. The... (More)
Objective: To evaluate the cumulative risk of having a prostate cancer diagnosis in a repeated screening situation in relation to the free-to-total prostate specific antigen ratio (F/T-PSA). Patients and Methods: The present study includes 1385 men (aged 50-70 years) who underwent prostate biopsy for the first time in the screening program that started in 1995. In case of a benign finding, the men have been followed biennially and new biopsies performed in case of persistently elevated PSA. The cumulative risk to be diagnosed with prostate cancer until July 1, 2002 was calculated by the Kaplan-Meier method and comparison was made between different levels of T-PSA and F/T-PSA ratios. Results: Of 2129 biopsies 469 showed cancer. The cumulative 5-year risk to be diagnosed with prostate cancer was significantly dependent of the F/T-ratio. The risk for men with a T-PSA of 3-5.99 ng/ml was 16% [6-25%] for those who had a ratio of >30% and 44% [34-60%] for those with a ratio of <10%. The corresponding difference for patients with a T-PSA of 6-9.99 ng/ml was even more pronounced: 21% [0-42%] vs. 80% [64-96%]. Conclusion: By completing the T-PSA measurement with the F/T-PSA ratio it is possible to significantly better assess the cumulative prostate cancer risk within the next five years (without the aid of further urological work-up). (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
PSA, screening, free-to-total, prostate specific antigen, prostate cancer, diagnosis
in
European Urology
volume
45
issue
2
pages
160 - 165
publisher
Elsevier
external identifiers
  • pmid:14734000
  • wos:000188641500006
  • scopus:0742306801
ISSN
1873-7560
DOI
10.1016/j.eururo.2003.09.008
language
English
LU publication?
yes
id
f48c7c95-c565-4265-b2e2-586551685945 (old id 288770)
date added to LUP
2007-10-16 14:28:06
date last changed
2017-01-01 07:26:18
@article{f48c7c95-c565-4265-b2e2-586551685945,
  abstract     = {Objective: To evaluate the cumulative risk of having a prostate cancer diagnosis in a repeated screening situation in relation to the free-to-total prostate specific antigen ratio (F/T-PSA). Patients and Methods: The present study includes 1385 men (aged 50-70 years) who underwent prostate biopsy for the first time in the screening program that started in 1995. In case of a benign finding, the men have been followed biennially and new biopsies performed in case of persistently elevated PSA. The cumulative risk to be diagnosed with prostate cancer until July 1, 2002 was calculated by the Kaplan-Meier method and comparison was made between different levels of T-PSA and F/T-PSA ratios. Results: Of 2129 biopsies 469 showed cancer. The cumulative 5-year risk to be diagnosed with prostate cancer was significantly dependent of the F/T-ratio. The risk for men with a T-PSA of 3-5.99 ng/ml was 16% [6-25%] for those who had a ratio of &gt;30% and 44% [34-60%] for those with a ratio of &lt;10%. The corresponding difference for patients with a T-PSA of 6-9.99 ng/ml was even more pronounced: 21% [0-42%] vs. 80% [64-96%]. Conclusion: By completing the T-PSA measurement with the F/T-PSA ratio it is possible to significantly better assess the cumulative prostate cancer risk within the next five years (without the aid of further urological work-up).},
  author       = {Aus, G and Becker, Charlotte and Franzen, S and Lilja, Hans and Lodding, P and Hugosson, J},
  issn         = {1873-7560},
  keyword      = {PSA,screening,free-to-total,prostate specific antigen,prostate cancer,diagnosis},
  language     = {eng},
  number       = {2},
  pages        = {160--165},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio},
  url          = {http://dx.doi.org/10.1016/j.eururo.2003.09.008},
  volume       = {45},
  year         = {2004},
}